Tacit is an applied research lab that combines artificial intelligence with life‑science expertise to create a model‑centric, massively parallelized approach to drug discovery. By developing autonomous AI‑driven pipelines, they aim to design the blueprint for next‑generation pharmaceutical companies and accelerate the development of new medicines.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery relies on sequential, labor-intensive processes and limited experimental throughput, resulting in long development timelines and high costs. The lack of integrated, autonomous systems hampers the ability to explore large chemical spaces efficiently.
Solution
Tacit operates as an applied research lab that combines artificial intelligence with life‑science expertise to create a model‑centric, massively parallelized drug discovery workflow. By building autonomous platforms that can generate predictive molecular models, design candidate structures, and orchestrate high‑throughput synthesis and testing, Tacit accelerates the iteration cycle from concept to validated lead. The platform integrates AI‑driven design with automated laboratory execution, enabling rapid evaluation of thousands of compounds in parallel. This approach aims to define a blueprint for next‑generation pharmaceutical companies that can bring therapies to market more quickly and cost‑effectively.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to accelerate early‑stage discovery, as well as contract research organizations that require high‑throughput, AI‑enabled screening capabilities.
Features
- AI‑driven generative models that predict target affinity, ADMET properties, and synthetic feasibility
- Automated design‑test‑iterate loop linking computational chemistry with high‑throughput synthesis and assay platforms
- Scalable cloud infrastructure for managing parallel experiments and data analytics
- Integrated data pipeline that captures experimental results to continuously retrain and improve predictive models
- Modular architecture allowing customization for different therapeutic areas and target classes